Klacid Sr

Clarithromycin, the active ingredient in Klacid Sr, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats a range of bacterial infections, including pneumonia, sinusitis, bronchitis exacerbations, skin infections, and Helicobacter pylori‑related conditions, in adult patients.

GNH USA supplies Klacid Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to healthcare providers across multiple continents. Ensuring reliable supply chains and timely delivery, GNH USA supports global treatment needs.

Clarithromycin is a macrolide antibiotic indicated for several bacterial infections affecting the respiratory tract, skin and gastrointestinal system.

- Community-acquired pneumonia: effective treatment of susceptible bacterial pathogens causing lung infection. - Acute bacterial sinusitis: resolves sinus inflammation caused by susceptible bacteria. - Acute bacterial exacerbations of chronic bronchitis: reduces bacterial load and improves symptoms. - Skin and soft tissue infections: treats infections such as cellulitis and erysipelas caused by susceptible organisms. - Helicobacter pylori eradication: used in combination regimens to eliminate H. pylori infection.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset that may occur shortly after taking the medication. - Diarrhea: loose, watery stools that can be intermittent during therapy. - Taste disturbance: a temporary altered or metallic taste in the mouth. - Headache: mild to moderate headache that usually resolves without intervention.

Serious or Rare Side Effects: - Clostridioides difficile-associated diarrhea: severe colitis presenting with profuse watery stools and abdominal pain, requiring prompt medical care. - QT interval prolongation: elongation of the cardiac repolarization phase that can predispose to serious arrhythmias. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare, life‑threatening skin and mucous membrane reactions characterized by blistering and detachment.

When prescribing clarithromycin, clinicians should consider several safety measures to minimize risks.

- Assess renal function: adjust therapy in patients with significant renal impairment. - Monitor liver enzymes: watch for signs of hepatotoxicity during treatment. - Avoid use in patients with known macrolide allergy: risk of hypersensitivity reactions. - Use caution in patients with QT prolongation risk: evaluate cardiac history and concomitant drugs. - Discuss pregnancy and breastfeeding: clarithromycin is Category B; benefits should outweigh potential risks. - Store at room temperature: keep tablets in the original container, protect from moisture and heat.

Clarithromycin interacts with several medicines; some combinations must be avoided while others require careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic clarithromycin levels. - Concomitant QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Statins (especially simvastatin, lovastatin): increased risk of myopathy and rhabdomyolysis. - Warfarin: clarithromycin may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: plasma concentrations may rise, leading to toxicity. - Carbamazepine: may reduce clarithromycin concentrations, decreasing efficacy.